Idiopathic Pulmonary Fibrosis News and Research

RSS

Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.

AI-designed drug candidate reverses biological age in clinical study

Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

7 Sep 2026

Insilico Medicine releases frontier AI models for drug discovery

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the release of a series of frontier specialist models for chemistry and biology, trained through its MMAI Gym for Science framework.

2 Sep 2026

FDA grants fast track designation to Insilico's AI-designed mesothelioma drug candidate

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that ISM6331, a novel, potential best-in-class pan-TEAD inhibitor driven by Insilico's proprietary AI, has received Fast Track Designation (FTD) from the U.S.

29 Jul 2026

Discovery of lung protein offers hope for pulmonary fibrosis

Pulmonary fibrosis is a deadly disease where scar tissue grows in the lungs, making breathing more difficult. Approximately 2,170 Australians are diagnosed annually with idiopathic pulmonary fibrosis (IPF), a form of the disease with no known cause and very few treatments.

16 Jul 2026

Insilico Medicine highlights AI drug discovery progress at executive summit

Dr. Alex Aliper, Co-founder and President of Insilico Medicine, will attend the AI for Good Global Summit 2026 in Geneva, Switzerland, on July 7.

3 Jul 2026

Machine learning identifies natural compound to treat lung disease

A new study published in Engineering has combined machine learning (ML) and experimental validation to identify dihydromyricetin (DHM), a natural flavonoid, as a potent inhibitor of the TGF-β/ALK5 signaling cascade with therapeutic potential for idiopathic pulmonary fibrosis (IPF).

16 Jun 2026

New findings highlight risks and therapeutic targets in systemic sclerosis

Systemic sclerosis is a rare connective tissue disorder characterised by autoimmune features with vascular manifestations, causing fibrosis of the skin and internal organs.

7 Jun 2026

Blood protein signature can predict lung cancer risk before diagnosis

Researchers at the Francis Crick Institute and University College London (UCL), funded by Cancer Research UK and the European Research Council (ERC), have identified a 14-protein signature in the blood that can predict lung cancer risk more than five years before diagnosis.

4 Jun 2026

New imaging method distinguishes inflammation from lung fibrosis

A new SPECT/CT imaging approach can accurately differentiate inflammation from fibrosis in interstitial lung disease (ILD) patients, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.

1 Jun 2026

Qureight establishes Scientific Advisory Board focused on pulmonary hypertension

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has established a Scientific Advisory Board (SAB) focused on pulmonary hypertension (PH).

From Qureight 11 May 2026

Virginia Tech team identifies proteins that can reverse lung scarring

A Virginia Tech team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing that blocking two proteins can halt and even reverse lung scarring in pre-clinical models.

28 Apr 2026

Proteomics and AI bring earlier risk prediction into sharper focus

This review examines how high-throughput proteomics is expanding precision medicine by improving biomarker discovery, disease prediction, and drug development. It also shows how AI is helping researchers interpret complex proteomic data while highlighting major barriers such as standardization, validation, and clinical translation.

19 Apr 2026

Why AI is becoming a powerful tool in cancer drug discovery

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical translation, with an AI-designed TNIK inhibitor trial serving as an important proof-of-feasibility reference point. It argues that precision oncology could benefit from AI-driven integration of multi-omics, federated learning, and adaptive trial design, but only if validation, fairness, interpretability, and regulatory alignment improve.

16 Apr 2026

Researchers identifiy a promising strategy to reverse pulmonary fibrosis

Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it.

30 Mar 2026

p38 MAPK drives epigenetic activation of fibrotic genes in lung fibroblasts

A new research paper was published in Volume 18 of Aging-US on March 3, 2026, titled "P38 MAPK is involved in epigenetic regulation of fibrotic genes in replication induced senescence in lung fibroblasts."

10 Mar 2026

Generative AI aids discovery of ISM3830's novel scaffold

Casitas B-lineage lymphoma-b (CBLB) is an E3 ubiquitin–protein ligase that functions as an intracellular checkpoint and master negative regulator of T‑cell and natural killer (NK) cell activation, playing a central role in modulating T-cell activation and immune tolerance, and its inhibition enhances T cells and NK cells function, also provides a strategy for the function restoration of exhausted T cells.

1 Dec 2025